HXL AU0000111932

Rapporto

Tempo differito Australian Stock Exchange - 08:10 27/06/2022
0.0350	AUD		-12.50%

24/06	Le azioni australiane sono in rialzo grazie all'aumento dell'IT, in mezzo alla caccia alle occasioni	MT
24/06	Hexima condurrà una revisione dettagliata dei dati dello studio di fase 2 sul pezadeftide dopo i risultati 'non conclusivi'; le azioni crollano del 78%.	MT
24/06	Hexima Limited annuncia i risultati preliminari dello studio clinico di Fase II di Pezadeftide	CI

Notizie

Altre lingue

Pubblicazioni ufficiali

Notizie del settore

Notizie in altre lingue su HEXIMA LIMITED

24/06	Australian Shares Jump on IT Boost Amid Bargain Hunting
24/06	Hexima to Conduct Detailed Review of Pezadeftide Phase 2 Trial Data after 'Inconclusive..
24/06	Hexima Limited Announces Preliminary Results of Phase II Clinical Study of Pezadeftide
29/04	HEXIMA: ShareCafe Presentation
28/04	HEXIMA: Notification regarding unquoted securities - HXL
05/04	HEXIMA: Investor Webinar on Today
24/02	HEXIMA: Application for quotation of securities - HXL
24/02	HEXIMA: Appendix 4D and Interim Financial Statements
24/02	Hexima Limited Reports Earnings Results for the Half Year Ended December 31, 2021
08/02	HEXIMA: Notification regarding unquoted securities - HXL
01/02	HEXIMA: Application for quotation of securities - HXL
30/01	HEXIMA: Quarterly Activities Report and Appendix 4C
04/01	Hexima Appoints Commercial Chief
03/01	Phillip Rose Appoints Phillip Rose as Chief Commercial Officer
2021	HEXIMA: Notification regarding unquoted securities - HXL
2021	HEXIMA: Notification regarding unquoted securities - HXL
2021	Hexima Names New Chief Development Officer
2021	HEXIMA: CEO's Presentation
2021	Hexima Limited Announces Cessation of Marilyn Anderson as Executive Director
2021	Hexima Limited Announces Appointment of Shari Lipner as Member of its Scientific Adviso..
2021	Hexima Limited Announces Appointment of Nancy Sacco as Chief Development Officer
2021	Hexima Completes Oversubscribed Share Purchase Plan
2021	HEXIMA: Application for quotation of securities - HXL
2021	Hexima Limited Announces Company Secretary Change
2021	3,559,437 Ordinary Shares of Hexima Limited are subject to a Lock-Up Agreement Ending o..
2021	Jake Nunn Joins Board of Hexima Limited as Non-Executive Director, effective 1 Septembe..
2021	HEXIMA: 2021 Annual Financial Report
2021	Hexima Limited Reports Earnings Results for the Full Year Ended June 30, 2021
2021	Hexima Limited Auditor Raises 'Going Concern' Doubt
2021	HEXIMA: Secures Chinese Patent for Fungal Nail Infection Treatment; Shares Surge 12%
2021	Hexima Limited Announces Design Patent for Pezadeftide Commercial Packaging
2021	Hexima Limited Announces Completion of Enrolment in Phase IIb Clinical Trial
2021	HEXIMA: Expects to Secure European Patent for Nail Fungal Infection Treatment
2021	Hexima Limited Extends Its Patent Protection for Pezadeftide
2021	HEXIMA: Fungal Nail Infection Treatment Receives INN Designation
2021	HEXIMA: Secures Patent for Fungal Nail Infection Treatment
2021	Hexima Limited to Present Clinical Data from its Phase I/IIa Clinical Trial of HXP 124 ..
2021	HEXIMA: R&D Webinar on TodayOpens in a new Window
2021	HEXIMA: SAB Formation and R&D Video ConferenceOpens in a new Window
2021	HEXIMA: Half Year Report and AccountsOpens in a new Window
2021	Hexima Limited Announces Earnings Results for the Six Months Ended 31 December 2020
2021	Hexima Limited Updates Timeline to Phase 2B Results
2020	Hexima Limited has completed an IPO in the amount of AUD 3.280771 million.
2020	Hexima Limited Reports Earnings Results for the Year Ended June 30, 2019
2020	Hexima Limited has filed an IPO in the amount of AUD 7.5 million.
2020	Hexima Limited Reports Earnings Results for the Full Year Ended June 30, 2020
2020	Hexima Limited Auditor Raises 'Going Concern' Doubt
2020	Hexima Limited announced that it has received AUD 5.5 million in funding
2019	Hexima Limited Auditor Raises 'Going Concern' Doubt
2012	Hexima Limited Announces Unaudited Consolidated Earnings Results for Six Months Ended D..

Prossimi eventi del settore

22/07/22	LONZA GROUP AG: Primo semestre 2022 Pubblicazione dei risultati
26/07/22	IQVIA HOLDINGS INC.: Primo semestre 2022 Pubblicazione dei risultati (proiezione)
28/07/22	SEAGEN INC.: Primo semestre 2022 Pubblicazione dei risultati (proiezione)
03/08/22	MODERNA, INC.: Primo semestre 2022 Pubblicazione dei risultati (proiezione)

Più eventi

Settore

Sanità
	Biotecnologia/Farmaceutici
		Biotecnologia e ricerca medica
			Biotecnologia
				Biotecnologia e ricerca medica - Altri